1. Home
  2. SCLX vs IKNA Comparison

SCLX vs IKNA Comparison

Compare SCLX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • IKNA
  • Stock Information
  • Founded
  • SCLX 2011
  • IKNA 2016
  • Country
  • SCLX United States
  • IKNA United States
  • Employees
  • SCLX N/A
  • IKNA N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCLX Health Care
  • IKNA Health Care
  • Exchange
  • SCLX Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • SCLX 81.7M
  • IKNA 74.8M
  • IPO Year
  • SCLX N/A
  • IKNA 2021
  • Fundamental
  • Price
  • SCLX $0.42
  • IKNA $1.53
  • Analyst Decision
  • SCLX Strong Buy
  • IKNA Buy
  • Analyst Count
  • SCLX 3
  • IKNA 2
  • Target Price
  • SCLX $11.33
  • IKNA $3.00
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • IKNA 394.0K
  • Earning Date
  • SCLX 01-07-2025
  • IKNA 11-07-2024
  • Dividend Yield
  • SCLX N/A
  • IKNA N/A
  • EPS Growth
  • SCLX N/A
  • IKNA N/A
  • EPS
  • SCLX N/A
  • IKNA N/A
  • Revenue
  • SCLX $50,833,000.00
  • IKNA $659,000.00
  • Revenue This Year
  • SCLX $32.77
  • IKNA N/A
  • Revenue Next Year
  • SCLX $50.71
  • IKNA N/A
  • P/E Ratio
  • SCLX N/A
  • IKNA N/A
  • Revenue Growth
  • SCLX 9.41
  • IKNA N/A
  • 52 Week Low
  • SCLX $0.40
  • IKNA $1.22
  • 52 Week High
  • SCLX $2.63
  • IKNA $2.29
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 29.75
  • IKNA 38.40
  • Support Level
  • SCLX $0.43
  • IKNA $1.62
  • Resistance Level
  • SCLX $0.51
  • IKNA $1.94
  • Average True Range (ATR)
  • SCLX 0.06
  • IKNA 0.09
  • MACD
  • SCLX -0.01
  • IKNA -0.01
  • Stochastic Oscillator
  • SCLX 7.30
  • IKNA 3.53

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: